UB Paderborn / Katalog / Suche / in CDI

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

Histopathology, 2008-06, Vol.52 (7), p.797-805

2008

Volltextzugriff (PDF)

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

Journal of clinical pathology, 2008-01, Vol.61 (1), p.89-94

2008

Volltextzugriff (PDF)

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Annals of oncology, 2013-11, Vol.24 (11), p.2761-2766

2013

Volltextzugriff (PDF)

Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma

Diseases of the esophagus, 2015-05, Vol.28 (4), p.380-385

2015

Volltextzugriff (PDF)

An alternative-exon database and its statistical analysis

DNA and cell biology, 2000-12, Vol.19 (12), p.739

2000

Volltextzugriff (PDF)

Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer

Prostate cancer and prostatic diseases, 2008-06, Vol.11 (2), p.166-172

2008

Volltextzugriff (PDF)

3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer

European journal of cancer supplements, 2007-09, Vol.5 (4), p.272-272

2007

Volltextzugriff (PDF)

Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma: HER2 expression in esophageal cancer

Diseases of the esophagus, 2015-05, Vol.28 (4), p.380-385

2015

Volltextzugriff (PDF)

Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.PD10-01-PD10-01

2010

Volltextzugriff (PDF)

The STAR/GSG Family Protein rSLM-2 Regulates the Selection of Alternative Splice Sites

The Journal of biological chemistry, 2001-03, Vol.276 (12), p.8665-8673

2001

Volltextzugriff (PDF)

Molecular analysis of hormone refractory prostate cancer biopsies supports the rationale of using mTOR inhibitors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.21126-21126

2007

Volltextzugriff (PDF)

Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4641-4641

2006

Volltextzugriff (PDF)

ErbB2 diagnostics in breast cancer - an update

Der Pathologe, 2009-03, Vol.30 (2), p.147-155

2009

Volltextzugriff (PDF)

HER2 positivity in advanced gastric cancer is comparable to breast cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15057-15057

2007

Volltextzugriff (PDF)

Gene expression analysis of hormone-refractory prostate cancer in transurethral resection samples

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4778-4778

2005

Volltextzugriff (PDF)

Her2-Diagnostik beim Magenkarzinom: Was ist anders im Vergleich zum Mammakarzinom?

Der Pathologe, 2010-05, Vol.31 (3), p.208-217

2010

Volltextzugriff (PDF)

Alternative Splicing Determines the Intracellular Localization of the Novel Nuclear Protein Nop30 and Its Interaction with the Splicing Factor SRp30c

The Journal of biological chemistry, 1999-04, Vol.274 (16), p.10951-10962

1999

Volltextzugriff (PDF)

p59 super(f) super(y) super(n)-mediated phosphorylation regulates the activity of the tissue-specific splicing factor rSLM-1

Molecular and cellular neuroscience, 2004-09, Vol.27 (1), p.8-21

2004

Volltextzugriff (PDF)

Biomedical marker molecules for cancer – current status and perspectives

Drug Discovery Today: Targets, 2004-12, Vol.3 (6), p.228-237

2004

Volltextzugriff (PDF)

Aktuelles zur ErbB2-Diagnostik beim Mammakarzinom

Der Pathologe, 2009-03, Vol.30 (2), p.147-155

2009

Volltextzugriff (PDF)

Her-2/neu analysis--new data?

Verhandlungen der Deutschen Gesellschaft fur Pathologie, 2006, Vol.90, p.107

2006

Volltextzugriff (PDF)

The in vivo minigene approach to analyze tissue-specific splicing

Brain research. Brain research protocols, 1999-12, Vol.4 (3), p.383-394

1999

Volltextzugriff (PDF)

ErbB2 diagnostics in breast cancer--an update

Der Pathologe, 2009-03, Vol.30 (2), p.147-155

2009

Volltextzugriff (PDF)

Integrative vector for constructing single-copy translational fusions between regulatory regions of Bacillus subtilis and the bgaB reporter gene encoding a heat-stable β-galactosidase

FEMS microbiology letters, 1997-05, Vol.150 (1), p.49-54

1997

Volltextzugriff (PDF)

Gene expression profile in hormone refractory prostate cancer

Urologe. Ausgabe A, 2007-09, Vol.46 (9), p.1117

2007

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma

An alternative-exon database and its statistical analysis

Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer

3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer

Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma: HER2 expression in esophageal cancer

Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience

The STAR/GSG Family Protein rSLM-2 Regulates the Selection of Alternative Splice Sites

Molecular analysis of hormone refractory prostate cancer biopsies supports the rationale of using mTOR inhibitors

Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC)

ErbB2 diagnostics in breast cancer - an update

HER2 positivity in advanced gastric cancer is comparable to breast cancer

Gene expression analysis of hormone-refractory prostate cancer in transurethral resection samples

Her2-Diagnostik beim Magenkarzinom: Was ist anders im Vergleich zum Mammakarzinom?

Alternative Splicing Determines the Intracellular Localization of the Novel Nuclear Protein Nop30 and Its Interaction with the Splicing Factor SRp30c

p59 super(f) super(y) super(n)-mediated phosphorylation regulates the activity of the tissue-specific splicing factor rSLM-1

Biomedical marker molecules for cancer – current status and perspectives

Aktuelles zur ErbB2-Diagnostik beim Mammakarzinom

Her-2/neu analysis--new data?

The in vivo minigene approach to analyze tissue-specific splicing

ErbB2 diagnostics in breast cancer--an update

Integrative vector for constructing single-copy translational fusions between regulatory regions of Bacillus subtilis and the bgaB reporter gene encoding a heat-stable β-galactosidase

Gene expression profile in hormone refractory prostate cancer

Suchergebnisse filtern